SynAct Pharma AB
Nasdaq Stockholm · LEI 549300RRYIEFEQ72N546· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Operating loss of $11.4M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- ROE
- -65.1%
- Debt-to-equity
- 29.5%
- Equity ratio
- 77.2%